INTRODUCTION

ROPARK 0.25MG contains Ropinirole which belongs to the group of medicines called dopamine agonists. It is used to treat Parkinson’s disease and symptoms of moderate to severe idiopathic Restless Legs Syndrome (RLS). Parkinson’s disease is a progressive neuro-degenerative disorder, that predominately affects the dopamine-producing neurons in the brain. It is characterized by rigidity, tremor, defective posture and gait and drooling with or without dementia. RLS is CNS disorder characterized by an irresistible urge to move the affected legs or arms, usually associated with tingling, burning or prickling sensation. It commonly occurs during the periods of rest or inactivity such as sitting or lying down, especially in bed, and are worse in the evening or at night.

ROPARK 0.25MG acts similar to that of natural dopamine in the brain and helps in the reduction of symptoms of Parkinson’s disease and RLS. While taking this medicine, inform your doctor if you experience any unusual behaviour (such as an unusual urge to gamble or increased sexual urges). The most common side effect of this medicine is worsening of RLS. You might feel that your symptoms started more earlier than usual or be more intense or affect other previously unaffected limbs. Others include dizziness, drowsiness, feeling tired, nausea, vomiting, stomach pain or dyskinesia. Contact your doctor if any of the symptoms bothers you.

USES OF ROPARK 0.25MG

• Treats Parkinson’s disease, Idiopathic Restless Legs Syndrome

HOW ROPARK 0.25MG WORKS

Dopamine is a chemical messenger that is required for controlling body movements (motor activity) in the brain. Ropinirole has neurological effects similar to that of natural dopamine. Stimulation of dopamine receptors by ropinirole improves motor function which helps in the reduction of symptoms of Parkinson’s disease and Restless Legs Syndrome.

DIRECTIONS FOR USE

Take ROPARK 0.25MG as directed by your physician. It is taken preferably with food to avoid nausea. Swallow the medicine as whole with plenty of water. Do not crush or chew the medicine. Your doctor will decide the correct dose and duration for you depending upon your age, body weight and body condition. Continue to take this medicine, as long as your doctor tells you to do so, to obtain better results.

SIDE EFFECTS OF ROPARK 0.25MG

HOW TO MANAGE SIDE EFFECTS

Nausea or vomiting:

Try taking this medicine with, or just after meals. Stick to simple meals. Do not eat rich or spicy food.

Stomach pain:

Try to rest and relax. You can eat and drink slowly or have smaller and frequent meals. Keeping a heat pad on your stomach may also help. If still pain persists, speak to your doctor.

Feeling tired, dizzy or drowsy:

Try to rest and relax. Get enough sleep. Avoid travelling, driving vehicles or operating any machinery while you are feeling tired or dizzy.

WARNING & PRECAUTIONS

INTERACTIONS

Talk to your doctor, if you are taking,

• other medicines used to treat Parkinson’s disease or Restless Legs Syndrome (e.g. levodopa, Pramipexole, Selegiline)
• medicines used to treat other mental health problems (e.g. sulpiride)
• fluvoxamine (used to treat depression)
• Hormone Replacement Therapy (used for menstrual problems)
• metoclopramide (used to treat nausea and heartburn)
• antibiotics (e.g. ciprofloxacin or enoxacin)
• vitamin K antagonists (used to reduce blood clotting) e.g. warfarin

SYNOPSIS

MORE INFORMATION

Store below 20-25°C and keep out of reach of children.

FAQs ABOUT ROPARK 0.25MG

Can we stop taking ROPARK 0.25MG abruptly?

No. Do not stop taking this medicine, without consulting your doctor because it may lead to unpleasant withdrawal symptoms. Continue to take this medicine, as long as your doctor tells you to do so, to obtain better results.

Can ROPARK 0.25MG make RLS worse?

Yes. The most common side effect of this medicine is worsening of RLS. You might feel that your symptoms started more earlier than usual or be more intense or affect other previously unaffected limbs. Contact your doctor if this symptom bothers you.

Can ROPARK 0.25MG cause insomnia?

Yes. It can cause insomnia in some individuals, although not everybody gets them. Contact your doctor if this symptom bothers you.

Can ROPARK 0.25MG cause hallucination?

Yes. It can cause hallucinations in some individuals. Contact your doctor if this symptom bothers you.

REFERENCES

1. KD. Tripathi. Antiparkinsonian Drugs. Essentials of medical pharmacology. Seventh edition. 2013. Page - 430-431.

2. Elaine Sanders-Bush and Lisa Hazelwood. 5-Hydroxytryptamine (serotonin) and dopamine. Goodman & Gilman’s: The Pharmacological basics of Therapeutics. 12th Edition. New York McGraw Hill Medical 2011. Page – 358.

3. David G. Standaert and Erik D. Roberson. Treatment of Central Nervous System Degenerative disorders. Goodman & Gilman’s: The Pharmacological basics of Therapeutics. 12th Edition. New York McGraw Hill Medical 2011. Page – 616-617.

4. Gerald G. Briggs and Roger K. Freeman. R. A reference guide to fetal and neonatal risk: Drugs in Pregnancy and Lactation. Tenth Edition. 2015. Page – 3455-3456.

5. GlaxoSmithKline. REQUIP (Ropinirole Hydrochloride) IR Long-Term Phase 4 Study.  NIH U.S. National Library of Medicine ClinicalTrials.gov. [Revised on December 2010] [Accessed 8th December 2020] https://clinicaltrials.gov/ct2/show/NCT00485069

6. Prachaya Srivanitchapoom, Sanjay Pandey and Mark Hallett. Restless legs syndrome and pregnancy: A review. NCBI; PMC US National Library of Medicine, National Institute of Health. April 2014. [Accessed 8th December 2020] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058350/

7. John Lee. ROPIFORD-5. Johnleeindia.com. [Accessed 8th December 2020] https://johnleeindia.com/product/ropiford-5/

8. John Lee. ROPIFORD-3. Johnleeindia.com. [Accessed 8th December 2020] https://johnleeindia.com/product/ropiford-3/

9. John Lee. ROPIFORD-4. Johnleeindia.com. [Accessed 8th December 2020] http://johnleeindia.com/product/ropiford-4/

10. Generics [UK] Ltd, Gerard Laboratories, Mylan UK Healthcare Limited and Mylan Hungary Kft. Electronic Medicines Compendium (EMC). [Revised on October 2019] [Accessed 8th December 2020] https://www.medicines.org.uk/emc/files/pil.8779.pdf